Drug intelligence / Profile preview

ASCA101CC

Development stage: Preclinical
Lead developer: MetaFines
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

ASCA101CC is a preclinical-stage small molecule developed by MetaFines for the treatment of cachexia, specifically cancer-induced and chemotherapy-induced cachexia. The drug acts by modulating mitochondrial function and regulating muscle and fat metabolism to counteract the systemic wasting syndrome associated with advanced malignancies and cytotoxic treatments. It is being evaluated in both intravenous (IV) and oral (PO) formulations to address the metabolic imbalances that drive the progressive loss of body weight and muscle mass in oncology patients.

Targets

Neuraminidase

Beyond the preview

Go deeper on ASCA101CC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASCA101CC.

Explore the full profile